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ABSTRACT 
 
Background  :   
   Hypomagnesemia is an important but under diagnosed electrolyte 
abnormality in critically ill patients at IMCU. There are many studies to find the 
prevalence of hypomagnesemia and its effects on mortality and morbidity in 
IMCU patients. This study was cross sectional study, carried out in IMCU 
patients at Kilpauk Medical College and Hospital, to study on serum 
magnesium level & its effect on mortality and morbidity 
Aims and objectives: 
To study serum magnesium levels in patients admitted in intensive medical care 
unit within 24 hours of admission and find out hypomagnesemia, to determine 
the associated outcome in terms of 1. Length of stay in IMCU, need for 
ventilator support, duration of ventilator support, mortality and APACHE II.  
  2. To assess the primary critical medical conditions associated with 
hypomagnesemia  
  3. To detect other electrolyte abnormalities associated with hypomagnesemia if 
any  
   
 
 
Results: 
In our study, 53% patients had hypomagnesemia ,  47% had normal magnesium. 
Mean range of the APACHE score in the hypomagnesemic patients was higher 
(18.70 vs 10.09) , length of stay in ICU was longer( 4.75 vs 3.5 days), need for 
ventilator support was higher (35.8% vs10.6%), associated with higher 
hypokalemia (39 % vs. 12 %),  hypocalcemia  (32 % vs. 8 %)  and 
hyponatremia (45% vs 19%)  . It was more frequent in sepsis and higher 
mortality rates were higher (30% vs 8.5 % ).  Duration of ventilator support did 
not have correlation with magnesium level.  
Conclusion: 
Hypomagnesemia has a higher prevalence among the Patients in IMCU set up 
and associated with  higher APACHE score, longer stay in ICU, higher need of 
ventilatory support, higher mortality rates and higher electrolyte disturbances 
(hypokalemia, hypocalcemia , hyponatremia),  are noted  among these patients . 
It was predominantly present in sepsis. There was no correlation between 
hypomagnesium and duration of ventilator support. 
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INTRODUCTION 
 Magnesium is mainly seen in the intracellular fluid of all living cells and 
tissues and it is extremely essential for life. It is second most plentiful intra-
cellular cation after potassium; fourth most plentiful after sodium, potassium 
and calcium in humans. 
Magnesium plays  a vital role in the transfer of energy and also storage, 
utilization of energy  and it regulates as well as catalyzes >300 enzyme 
systems.
2
It acts as activator for many of the phosphate group transfer enzymes, 
for example, formation of ATP. It is found in certain enzymes, such as co-
carboxylase. The enzymes needing magnesium are involved in intermediary 
metabolism, transcellular ion transport, muscle contraction, oxidative 
phosphorylation. Some examples are alkaline phosphatase, hexokinase, 
fructokinase, phophofructokinase, adenyl cyclase, cAMP dependent kinases, 
etc. 
Mg is required for the formation of bones and teeth, maintains 
neuromuscular excitability, cardiac function and improves glucose tolerance by 
insulin dependent uptake of glucose, which is reduced in magnesium 
deficiency. Magnesium is attached to other nucleoside phosphates and nucleic 
acids and is needed for DNA synthesis. 
8 
 
Hypomagnesemia has been expected to develop in 20% to 65% of 
critically ill patients during course of their stay in intensive care unit
1
. Though it 
is common, it is frequently under diagnosed abnormality in clinical practice and 
easily mistaken for potassium deficit. 
Factors contributing to magnesium deficiency in critical care settings are 
reduced absorption due to altered gastrointestinal activity, malnutrition, renal 
loss of various drugs (e.g., digoxin and gentamicin also loop diuretics etc.), 
diabetic individuals, hypokalemia, hypocalcemia, poor content of magnesium in 
TPN solution. 
Hypomagnesemia in critically ill patients has been found to have a higher 
APACHE II score and causes an increased requirement for ventilatory support 
as well as its duration because hypomagnesemia causes muscle weakness and 
respiratory failure which leads very much difficult to weaning the patient from 
the ventilator. Prolonged stay in Intensive medical care unit (IMCU) is also 
associated with higher mortality and morbidity. Hypomagnesemia contributes 
to cellular alteration associated with other electrolyte abnormalities. It 
aggravates the mortality and morbidity, and is found to be an important 
predictor of poor patient outcome in critically ill patients. 
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Normal range for total serum Magnesium concentration in 
mmol/L 
(1 mmol/L=2mEq/L=2.43mg/dl) 
 
  
 
 
 
Patients admitted with low magnesium levels in intensive care units can 
affect the prognosis of patients compared to those having normal levels of 
magnesium that is hypomagnesemic patients have a guarded prognosis. Hence 
in an IMCU set up, monitoring of serum magnesium levels along with other 
electrolytes has a very important therapeutic as well as prognostic implication. 
 Our study was intended to see the status of serum magnesium level in 
acutely ill patients, evaluate the association of magnesium level to various 
organ failure and duration of stay, electrolyte disturbance, requirement for 
ventilatory support, length of ventilatory support, mortality rate. 
  HYPERMAGNESEMIA 
            NORMAL 
0.95
 0.75 
  HYPOMAGNESEMIA 
10 
 
Also this study was undertaken to establish the value of the 
APACHE II score in determining the morbidity and mortality of acutely ill 
medical patients with hypomagnesemia admitted in intensive medical care unit 
(IMCU). 
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AIMS AND OBJECTIVES 
1. To find out hypomagnesemia in patients admitted in intensive medical 
care unit within 24 hours of admission and to determine the associated 
outcome in terms of Length of stay in IMCU, need for ventilator support, 
duration of ventilator support, mortality, APACHE  II.  
2. To assess the primary critical medical conditions associated with   
hypomagnesemia 
3. To detect other electrolyte abnormalities associated with 
hypomagnesemia if any 
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REVIEW OF LITERATURE: 
Magnesium is a macro mineral, most essential for life, needed by body in 
large amounts. The average human body contains about 25 grams of 
magnesium. It acts as a part of the structure of the body because majority of 
magnesium is distributed in bone and functions as a cell regulator in chemical 
reactions throughout the body. 
Magnesium disorders are common in critically ill patients in intensive 
care unit. Various prospective studies showed that 52.5% of hypomagnesemic 
and 13.5% of hypermagnesemic ICU patients were associated with higher 
mortality
3
 .More than 80000 assays are being done every year in bigger 
institutions but there is controversy whether this is the best way to maximally 
benefit critically ill patients. 
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PHYSIOCHEMICAL PROPERTIES OF MAGNESIUM: 
Magnesium belongs to group 2 element in periodic table having atomic 
mass of 24.305 Da and a Specific gravity of 1.738
4,5,6. 
Magnesium binds water 
more than sodium, calcium and potassium.
 
 The ionic radius of dehydrated Mg is small which explains its 
antagonistic behavior to calcium. Also magnesium cannot pass through narrow 
channels in biological membranes which can be passed by calcium. 
 
SOURCES OF MAGNESIUM: 
Magnesium is widely distributed in vegetables, found in porphyry in 
group of chlorophyll of vegetable cells also in almost all animal tissues. Milk, 
eggs, cabbage, cauliflowers, fruits, cereals, beans, leafy vegetables and fish, 
nuts, almonds have particularly rich source and cheese, potatoes. Artificial 
foods and boiling, demineralised water contains low Mg content. Total Mg 
content in human body is 21 to 28g approximately or 20mmol/kg of fat free 
tissue. 
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DAILY REQUIREMENT OF MAGNESIUM: 
  In infants is around 100-150 mg, children-150-200 mg, in adult 
males 400mg, females 300mg, during  pregnancy and lactation 450 mg
8,9
.Doses 
above 600mg may cause diarrhoea. 
 
MAGNESIUM HOMEOSTASIS: 
 
 
 
ionized 
 
 
 
 
 
 
Intestinal absorption  
Renal excretion of magnesium 
     Bone Mg2+ 
ECF Mg 
        Protein bound Mg 
                   20-30% 
        Ionized Mg  
               55-70% 
Complexed Mg 
            5-15% 
                       Intracellular ionized Mg 
                      Mg bound to cell organelles 
15 
 
Magnesium gets absorbed by intestine, stored in bones and excreted by 
kidneys. Intestinal absorption of magnesium is balanced against excretion of 
magnesium by kidneys
12
. Body depends on magnesium in bones to maintain 
serum levels constantly, when there is presence of magnesium deficit. 
INTESTINAL ABSORPTION OF MAGNESIUM 
 It is absorbed by small intestine also from colon through a specific carrier 
system beginning within hour after consumption, follows at a steady rate for 
two to eight hours. In spite of intestinal absorption of dietary magnesium is 
about 30% to 50% approximately, when intake is low, the absorption rate is 
raised to 80%. Plasma concentration of magnesium in healthy individual is 
about 0.65-1.05mmol/L, while shortage of magnesium which is compensated 
by stored magnesium in bone and muscle. 
ABSORPTION PATHWAYS: 
Para cellular and transcellular pathways are the two pathways involved in 
Mg absorption. The former involves absorption via the small spaces within the 
epithelial cells. The latter involves active transfer of Mg through the epithelial 
cells which is subject to tight regulation. 
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Para cellular Mg transport in the epithelium of intestine occurs through 
unidentified claudins which occurring simultaneously with transcellular Mg 
transport through TRPM6 and TRPM7 apparent receptor potential channel 
melastatin group to increase Mg absorption. 
 
Paracellular pathway involves claudin proteins and transcellular involves 
TRPM6, TRPM7 to increase absorption of magnesium. Para cellular pathway 
which is a passive one contributes to 80-90% of Mg2+ absorption owing to the 
high luminal Mg2+ concentration and lumen positive transepithelial voltage of 
+5mV
17
. The low expression of claudins in ileum and distal colon makes them 
highly permeable to ions. 
TRPM6 and TRPM7 are expressed in the luminal side of enterocytes 
which help in transcellular pathway. The former is ubiquitously expressed 
whereas the latter is expressed majority in distal small intestine and colon in 
case of murine tissues. 
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FACTORS IN REGULATION: 
Disturbed magnesium absorption by low magnesium diet in take which is 
partly attributed by changes in colon containing TRMP6 expression and 
paracellular rate of transport owing to electrochemical gradient. It is shown that 
, 25 dihydroxy vitaminD3 stimulates intestinal  
Mg absorption exemplified by low vitD3 levels in patients of chronic renal 
disease having low Mg levels.VitD3 regulates the expression of claudins 2 and 
12 involved in paracellular pathway and doesn’t regulate the TRMP6 
expression in kidneys. 
 
 Low and high Mg2+ intake affects calcium metabolism as shown in 
mice.
13-15 
Though the actual mechanism is unknown, it is suggested that 
common transport mechanism from intestinal tract for both Ca and Mg 
suggested calcium sensing receptor CaSR has a regulatory role in this 
interaction. 
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TABLE 1 REGULATORY FACTORS IN MAGNESIUM ABSORPTION 
Increased Mg reabsorption due to Decreased Mg reabsorption due to 
Parathyroid hormone,GH Diuretics, fatty acids, phytates 
Vitamin D, neomycin,  Phosphorus depletion,phosphates 
Hypocalcemia, high protein intake Hypercalcemia, low protein intake 
Metabolic alkalosis Metabolic acidosis 
Intravascular volume depletion Intravascular volume expansion 
Hypomagnesemia and normal 
mucosal state 
Hypermagnesemia and damaged 
mucosa 
Increased requirement Decreased requirement 
 
MAGNESIUM STORAGE 
Magnesium stored in bone as largest amount hence it act as aenerger of 
bone .There occurs continuous interchange of Mg within bone and blood. Low 
plasma Mg leads to activation of osteoclasts causing bone resorption
13,14
. 
Muscle fibres also store magnesium where it regulates contraction of muscle by 
opposing action of calcium. 
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DISTRIBUTION OF MAGNESIUM IN THE BODY: 
• whole blood  2 to 4mg/100ml 
• CSF  3mg/100ml(Mg in CSF ½ as high as in plasma) 
• Muscle             21mg/100gm 
• 70 percent of the total magnesium is combined with calcium and 
phosphorus in the complex salts of bone. 
• Remainder in the soft tissues (liver and muscle -20mEq/l) and body 
fluids.It is the principal cation of the soft tissue. 
• Hyperthyroidism increases the exchangeable mg, whereas it is reverse 
in hypothyroidism. 
• Extracellular Mg contributes to only 1% of total Mg content which is 
found in serum and RBC. 
• Serum Mg is available in three fractions; either ionized 60%, protein 
bound 30% or complexed with other anions 10%. 
• RBC 5mEq/l. unbound portion of serum magnesium is the 
biologically active fraction. 
• ICF 5 to 20 mmol/L of which majority remain combined to proteins, 
molecules having negative charge, ATP. Only 1-5% remain ionized 
form. 
20 
 
The skeletal 2% and ECF magnesium pools interchange freely with each 
other, but not interchange with the intracellular pool, muscle contains 20% 
exchangeable magnesium. Mostly50–60% of magnesium present as surface 
replacer of the hydroxyapatite
16
, it is mineral component of bone. 
Bone acts as reservoir pool of magnesium to buffer acute changes of 
plasma Mg levels. With age, the Mg levels of bone decrease thus making it 
unavailable during Mg deprivation. 
 
RENAL HANDLING OF MAGNESIUM: 
Kidney plays a role in maintaining plasma magnesium level within 
normal limits. About 98% of magnesium filtered at glomeruli is reabsorbed 
• 2/3 rd of excreted magnesium excreted  in the feces 
• 0.75 mEq of Mg is lost daily in perspiration in normal health with 
normal diet. Loss is much increased with visible frank sweating 
• 1/3rd into the urine; it varies with plasma magnesium concentration.   
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PROXIMAL TUBULE 
Of the total serum magnesium, about 80% is filtered in kidneys, of which 
more than 95% is reabsorbed in tubular system.10-25% reabsorption takes place 
in PCT in adult kidney. 
  Compared to other ions, absorption of Mg in proximal tubules remain 
miniscule. As more and more water gets reabsorbed, Mg concentration 
increases and once gradient is generated passive paracellular transport takes 
place which leading to 10-25% of Mg reabsorption.
18-20 
 
 
 
 
 
 
 
 
Fig 2 Magnesium reabsorption along the nephron 
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LOOP OF HENLE -THICK ASCENDING LIMB 
Majority of magnesium reabsorption occurs via cortical dense ascending 
limb (CTAL) of Loop of Henle (2/3 rd of magnesium).This is a passive 
paracellular transport driven by NKCC2 created lumen positive trans epithelial 
voltage. Paracellin-1 regulates paracellular through creation of pore permitting 
calcium and magnesium flow down their electrochemical gradient. It is shown 
that claudins 16 and 19 play role by forming cation selective tight junctions. 
 Na
+
 and Cl
-
 enter the ascending loop cells through              Na
+
K
+
Cl
2-
 
channel and leaves the cells through Na
+
K
+
 ATP ase, kidney specific Cl
-
 
channels.K
+
 gets recycled into lumen via renal outer medullary K
+
 channel. 
This maintains the positive potential in lumen which activates Mg transport.Use 
of diuretics like frusemide which inhibit NKCC2 channel abolishes this positive 
potential leading to increased excretion of Mg causing hypomagnesemia. 
Magnesium reabsorption in cortical thick ascending is influenced by 
many hormones (such as PTH, Calcitonin, Glucagon, Arginine, Vasopressin) as 
well as no hormonal factors (magnesium restriction, acid base balance, 
potassium depletion)
22-23
. 
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Restriction of dietary magnesium leads to renal magnesium conservation 
along with diminished urinary excretion of magnesium and this adaptation of 
magnesium transport occurs both in CTAL and distal tubule. 
Magnesium and calcium reabsorption is inhibited by elevation of 
magnesium and calcium concentration, leading to hypercalciuria and 
hypermagnesuria. 
This phenomenon is explained by the identification of a Ca-Mg sensing 
receptor located on the peritubular sides of TAL and distal tubule cells. Salt 
absorption in CTAL is diminished by loop diuretics such as furosemide, 
bumetanide, other factors decreasing magnesium reabsorption are potassium 
depletion, phosphate restriction, etc,
21 
 
Ca-Mg sensing receptors: 
Ca-Mg sensing receptor localized to the basolateral membrane influences 
the calcium-magnesium transport in TAL. It is activated by a rise in plasma Ca-
Mg receptor causing reduction in NaCl reabsorption and Vte, thus inhibiting 
reabsorption of Calcium and Magnesium. 
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The signal transduction pathway includes stimulation of arachidonic acid 
(AA) production through direct or indirect activation of phospholipase A2 
(PLA2), which is metabolized via the cytochrome P450 pathway to active 
metabolite that inhibits the apical potassium channel and, perhaps, the Na
+
, 
K
+
,2Cl
-
 co transporter activity, thereby reducing the lumen-positive voltage and 
paracellular transport of divalent cations. The calcium-magnesium-sensing 
receptor probably also directly or indirectly (by raising intracellular Ca2+) 
inhibits adenylate cyclase and causes decrease of hormone stimulated divalent 
cation transport. 
Fig 3 MAGNESIUM TRANSPORT PATHWAY IN THE LOOP OF 
HENLE 
. 
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DISTAL CONVOLUTED TUBULE 
10% of magnesium reabsorption takes place in DCT, which is the most 
important part in fine adjustment of renal magnesium excretion. Magnesium 
cation abnormal, which is coded by TRPM6 gene facilitates apical entry of 
magnesium, while basolateral exit is through a Mg/Na interchange mechanism. 
Active transcellular transport mechanism is the main mechanism for Mg 
reabsorption in DCT, and is closely related to NCCT generated lumen positive 
voltage
25
. Mutation in NCCT leads to hypokalemia, hypocalciuria and 
hypermagnesuria. Hypomagnesemia is linked with hypokalemia frequently, 
because reduced Mg in ICF which release the Mg dependant inhibition ROMK 
channels leading  to enhanced K
+
 loss in urine. 
 
FIG 4 Mg transport pathway in DCT. 
26 
 
TRMP Mg channel is regulated by EGF. The transmembrane potential is 
maintained by kv1.1k+ channels. Na+K+ ATPase at the basolateral membrane 
is balanced by transcription factor HNF1B. kir4.1  which is responsible for K+ 
recycling at basolateral side of cells. 
 
REGULATORY FACTORS 
 Pro endothelial growth factor is expressed only in distal convoluted 
tubule which on cleavage gets activated to EGF which in turn regulates TRMP 
6 activity. Oestrogen stimulates TRMP 6 activity. Hypermagnesuria in post 
menopausal women can be reversed by oestrogen substitution therapy. 
PTH diminishes excretion. Increased Ca and thyroid hormones, ADH, 
Growth hormone, aldosterone, alcohol, Ammonium chloride all increases 
excretion. Final magnesium concentration determined by interchange within 
passive mechanism and adjustment through active transporters present in 
absorption pathway after filtration. 
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ASSESSMENT OF MAGNESIUM
 
Assessment of Serum magnesium concentration is the routinely done test. 
But correlation between serum Mg and total body Mg is not well because as 
only 0.3% of it is in the serum. 
Magnesium is in: 
1. Serum 
2. RBC 
3. Leukocyte 
4. Muscle 
  
 Measured by: Balance studies, urine spot magnesium, ion uptake assay 
and magnesium retention test.  
 Measurement of free Mg levels by: Fluorescent probes and ion selective 
electrodes, NMR spectroscopy, Metallochrome dyes.
27
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In certain individuals, there may be a reduced total body magnesium, 
even though their serum Mg concentration are within limit and this condition is 
known as subtle chronic magnesium deficiency. Also there are some individuals 
whose total body magnesium content is within the physiological limits but 
serum Mg levels are low. Higher serum Mg levels are seen in vegetarians, after 
short periods of minimal exercise. During third trimester of pregnancy and after 
endurance exercises, lower serum Mg levels are observed. Hemolysis and 
serum bilirubin levels have a significant influence over the levels of Mg. Intra-
individual variability is also seen. 
 
Mg concentration is closely maintained within normal limits in healthy 
individuals.  The reference range of total magnesium levels in adult blood 
serum varies between 0.65-1.05 mmol/L ,ionized magnesium level range is 
between 0.55-0.75 mmol/L. Mg levels in serum is lower than that of in RBCs. 
Hence to avoid misinterpretation of Mg levels, one should be aware enough to 
avoid hemolysis.    
 
 In spite of many limitations, serum Mg levels remains as standard for a 
patient’s Mg status evaluation. Serum Mg measurement is feasible and not too 
expensive. It also helps in detecting rapid extracellular Mg level changes. 
29 
 
URINARY MAGNESIUM LEVELS: 
Measurement of Magnesium levels excreted in urine helps to know about 
the etiology for hypomagnesemia. Renal wasting of Mg is associated with 
higher urinary excretion whereas inadequate intake or absorption is associated 
with lower Mg levels in the urine. Since the urinary excretion level of Mg 
varies with circardian rhythm, one should always collect a 24hr urine specimen 
for appropriate evaluation. Fractional Mg excretion on a urinary spot specimen 
is calculated using the formula as follows. 
FEMg = UMg x PMg x 100/0.7 x PMg x UCr 
Where   FE Mg - Fractional Mg excretion 
          U Mg - Urinary Mg levels 
           P Mg - plasma Mg levels 
  UCr   - urinary creatinine concentration. 
MAGNESIUM LOADING TEST: 
To detect normo magnesemic magnesium depletion in critical care 
patients, Mg loading test is used
26
.When compared with serum test, it is the 
most sensitive test to detect the low Mg and assess the exchangeable Mg. 
30 
 
 
MAGNESIUM LVELS ASSESSMENT BY ION UPTAKE ASSAY 
Magnesium available in the forms of
24
Mg, 
25 
Mg,
26 
Mg.
26 
Mg is used for 
assessment of  intestinal Mg absorption.
28
Mg is radioactive for scientific use .In 
this method we can assess the initial change of ion content in the cells 
 
FUNCTION OF MAGNESIUM  
1. Cofactor in more than  300 enzymatic reaction; also involved in hormone 
binding protein, energy production and ATP which is required for muscle fibre 
contraction, protein and fat synthesis, cell reproduction and transport of 
substances across the cell barrier, glucose utilization, methyl group transfer. 
2. Plays major role in neuronal activity and muscle action, neurotransmitter 
release
29
 
3. Cardiac function, regulate heart beat, vascular tone, platelet activated 
thrombosis
28
 
4.  Endocrine function and bone formation. 
5. Crucial to glucose and fat break down, ATP metabolism, also for protein 
and antioxidants synthesis 
6. Also regulates cholesterol production 
31 
 
7. Maintains DNA structure and RNA, repair of DNA damage 
8. Maintains mineral balance 
9. Anticonvulsant 
10. Supports a healthy immune system, and bone strength 
11.  For protein synthesis and blood glucose regulation. 
 
USES: 
• Laxative for constipation  
• Bowel preparation for surgical or diagnostic procedures. 
• Antacid for acid indigestion. 
• To treat hypertension, dyslipidemia, mitral valve prolapsed, irregular 
heartbeat, chest pain , myocardial infarction 
• Used to treat  attention deficit-hyperactivity disorder and anxiety 
• also for  Lyme disease and fibromyalgia ,restless leg syndrome 
• to reduce blood glucose in diabetes and chronic fatigue syndrome 
• for kidney stones and migraine, osteoporosis 
• for premenstrual syndrome , leg cramps  and altitude sickness 
• also used to treat asthma and hay fever  
• multiple sclerosis, to preventing hearing loss  
• To  increase energy and endurance and for urinary incontinence 
32 
 
• Magnesium may be used tropically  to treat skin ulcers, carbuncles, boils  
• Magnesium used as cold and hot compressor to treating severe skin 
infections  
• Magnesium is useful for  bone growth 
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MAGNESIUM DEFICIENCY CAUSED BY 
Development of hypomagnesemia in critically ill patients categorized 
into decreased intake of Mg containing diet, those having disturbed 
intracellular-extracellular distribution and those with increased intestinal loss 
and renal loss
30-32
 
Decreased intake is a important determinant of magnesium levels 
.decreased intake of green leafy vegetables (chlorophyll Mg chelate of 
porphyrin). 
Serum magnesium level may fall in a number of clinical settings and 
contributes to a guarded prognosis for the patient especially when below 
1.7mg/dl. 
Acutely ill patients who develop hypomagnesemia fall into: 
• Those having  low  intake of Mg 
• Those having disturbed intracellular and extracellular distribution 
• Kidney or gastrointestinal tract loss 
  
34 
 
 
HYPOMAGNESEMIA CAUSES: 
I. Impaired intestinal absorption 
1. Primary infantile hypomagnesemia 
2. Malabsorption syndromes 
3. Vitamin D deficiency 
II. Increased intestinal loss 
1. Protracted vomiting and diarrhea 
2. Intestinal drainage and fistulae 
III. Impaired renal tubular reabsorption 
1. Genetic magnesium-wasting syndromes 
A. Gitelman syndrome 
B. Bartter syndrome 
C. Paracellin-1 mutations 
D. Na
+
 K
+
ATPase g-subunit mutations (FXYD2) 
E. Autosomal dominant, with low bone mass 
2. Acquired renal disease 
A. Tubulo interstitial disease 
B. Post obstruction, ATN (diuretic phase) 
C. Renal transplantation 
35 
 
3. Drugs and toxin 
A. Diuretics (loop, thiazide, osmotic) 
B. Cisplatin 
C. Pentamidine, foscarnet 
D. Cyclosporine 
E. Aminoglycosides, amphotericin B 
IV.   Extracellular fluid volume expansion 
1. SIADH 
2. Diabetes mellitus  
3. Hyper calcemia 
4. Hyper aldosteronism 
5. Metabolic acidosis  
6. Phosphate depletion 
7. Hyperthyroidism 
V.     Rapid shifts from extracellular fluid 
1. Rapid intracellular redistribution 
A. Recovery from diabetic ketoacidosis 
B. Refeeding syndrome and catecholamines 
C. Correction of respiratory acidosis 
36 
 
2)  Accelerated bone formation 
A. Treatment of vitamin D deficiency 
B. Post parathyroidectomy 
C. Osteoblastic metastasis 
3)   Others: 
A. Malnutrition 
B. Phosphorous deficiency 
C. Total parenteral nutrition 
D. Citrated blood products 
E. Alcohol abuse 
F. Hungry bone syndrome 
G. Cardiopulmonary bypass 
H. Hypoalbuminemia 
I.  Pancreatitis, burns, excessive sweating 
J.  Pregnancy (3rd trimester) and lactation 
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CLINICAL AND LABORATORY FINDINGS 
Alterations in neuromuscular function  
Ataxia, tetany, seizures, tremor, nystagmus, apathy, vertigo, irritabilty, 
depression, psychosis, delirium, Muscle fasciculation, muscular weakness, 
alteration in mental status. 
Cardiovascular symptoms 
Arrythmia like atrial fibrillation, ventricular tachycardia, supraventricular 
tachycardia, torsades de pointes, Hypertension, Vasospasm, Increased vascular 
resistance 
 
Electrocardiogram changes: 
  QT interval prolongation and PR interval prolongation 
Widened QRS complex 
Flattening or inversion of T wave 
Depression of ST segment 
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Endocrine: 
Stimulates secretion of parathyroid hormone (PTH) in mild cases, 
Suppresses PTH secretion in severe cases, Insulin resistance 
Electrolyte disturbances 
Decreased potassium, calcium and phosphorous 
Respiratory system 
Bronchoconstriction, Muscle weakness and Respiratory failure  
Miscellaneous  
Ileus, Increase in the levels of proinflammatory cytokines, Potentiation, 
of nephrotoxicity of cyclosporine and ototoxicity of gentamicin. 
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MAGNESIUM IN DISEASES 
SEPSIS: 
 Magnesium plays a significant role in patients with sepsis. 
Hypomagnesemia is linked with increased release of proinflammatory 
cytokines and endothelin
32
. Progressive deficiency of hypomagnesemia are 
strongly associated with increased mortality reported  by SALEM et al  showed 
in his study  that hypomagnesemia was associated with increased mortality in 
patients with sepsis and repletion of magnesium protects against Endotoxin 
mediated damage. 
 
HARKEMA et al   did a study and he infused ATP-MgCl2 to the animal 
models having sepsis and shock .It was found to refine the organ function and 
prolong the survival time. This   was due to the down regulation of 
inflammatory cytokines release like TNF-alpha and IL-6.  SOLIMAN ET AL 
showed in his study that sepsis is an independent risk factor for developing 
hypomagnesaemia in ICU set up. 
 
 
 
 
 
 
 
40 
 
 
CARDIAC ARRHYTHMIAS 
Mg has proven to be playing a good role in pathogenesis and treatment of 
supraventricular arrhythmias. Mg supplementation has increased the chance of 
conversion of atrial fibrillation to sinus rhythm. Magnesium was found to be 
superior to amiadarone in conversion of acute atrial tachyarrhythmia’s 
according to MORAN and co studies
33
.It was postulated that Mg exerts its anti 
arrhythmic action by blocking slow calcium channels and inhibiting sodium 
potassium ATP ase function. 
 
ACUTE MYOCARDIAL INFARCTION 
Magnesium blocks calcium flux into ischemic myocardial cells. It 
reduces vascular tone
34-36
. It reduces peripheral resistance. Magnesium 
increases the threshold for depolarisation. Thus helps to overcome the 
arrhythmias associated with acute myocardial infarction. 
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CARDIAC FAILURE AND MALIGNANT ARRHYTHMIAS 
Left ventricular failure and biventricular failure are associated 
hypomagnesemia. Elevated magnesuria is seen in these patients and it is controlled 
by loop diuretics. Animal studies have suggested that it would be beneficial to 
include magnesium in the acute management protocol of malignant arrhythmias 
with significant dysfunction of ventricles. 
BASHIR et al conducted a randomized, double blind crossover trial in 
which he tried using long term oral magnesium administration in congestive heart 
failure. The study was successful in showing a decrease in non-sustained 
monomorphic ventricular tachycardia (mVT) in nearly one fourth of patients. 21 
patients are included in the study. Similar results are obtained by SUETA et al in 
cases with symptomatic heart failure which was symptomatic treated with 
magnesium or placebo. Of the 30 patients included, none had a previous history of 
symptomatic arrhythmias. 
CEREMUZYNSKI et al showed excessive urinary magnesium in 72% and 
hypomagnesaemia in 38% of 78 patients with congestive heart failure with less 
than 40 % EF on admission. This study showed that administration of magnesium 
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decreased the incidences of non-sustained mVT largely but showed no difference 
in the adverse events risk. 
 
1068 patients were included in the PROMISE STUDY with New York Class 
III/IV heart failure for a RCT of milrinone. Magnesium levels were tested for all 
individuals during the trial. Serum magnesium was not a separate risk factor for 
sudden death. 
There is only some data to support that there is use of magnesium in patients 
with ventricular dysfunction who are presenting with a malignant arrhythmia. Until 
the other studies are over it should be kept reserved for those individuals with 
proven hypomagnesaemia.  
 
ATRIAL FIBRILLATION 
Sinus node function is not affected by magnesium. It delays atrioventricular 
nodal conduction and atrial refractory period.
37-38
 A trial on cardioversion of acute 
atrial fibrillation (AF) has shown improvement but this involved the patients with 
AVN tachycardia and compared the use of magnesium with verapamil. The other 
study showed there was some improvement in ventricular rate control but this was 
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not better than digoxin. This was contradicted by Frick et al who showed there was 
no effect on heart rate or variability in rate in individuals with chronic AF.  
Magnesium was proved to act as an antagonist of digoxin indirectly at the 
sarcolemmal Na
+
K
+
ATP ase pump. It has shown improvement in lowering the 
episodes of ventricular arrhythmias which is associated with digoxin toxicity. 
However the gold standard test remains Fab antibodies.  
TORSADE DE POINTES 
Torsade de pointes (TdP) is a form of polymorphic ventricular arrhythmia. It 
is associated with prolongation of QT interval. It is associated with the prominent 
U waves on the resting electrocardiogram. There is prolonged repolarisation and 
the development of early after depolarization on ECG. It may progress to 
ventricular fibrillation. In the long QT syndromes potassium ion channel 
dysfunction causes an intracellular surplus of positive charge, so delay 
repolarisation is mainly because of efflux of potassium ions. Delay of inactivation 
of calcium ion channels causes in late inflow causing EADs.  
These may reach threshold amplitude causing a ventricular arrhythmia. As 
the deep sub endocardium is most vulnerable to prolonged repolarisation and the 
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development of EAD the heterogeneous state of the myocardium causes a specific 
type of re-entrant arrhythmia. This is seen in the TdP pattern on ECG.  
 
The long QT syndrome which has the risk of development of TdP may be 
congenital or iatrogenic. It is associated with: 
• Anti arrhythmics class Ia and II 
• Butyrophenones and phenothiazines 
• Non-sedative antihistamines 
• Tricyclic antidepressant and cocaine 
• Antibiotics especially macrolides 
• Organophosphates 
• Antifungals 
 
It is also seen in subarachnoid haemorrhage, starvation and bradycardias. 
The aim of treatment in TdP are (a) to decrease the QT interval and (b) to alter the 
after depolarization effect. Present management of TdP is based on theoretical a 
concept which is supported by experimental evidence as there are no randomized 
control trials. 
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Intravenous magnesium sulphate 2g over one to two minutes reduces EADs 
in the emergency situation. Studies support the fact that it reduces the amplitude of 
EADs to sub-threshold levels, It does so by inhibiting the influx of calcium. This 
has to be accompanied by correction of hypokalemia to a serum concentration of 
>4.5 mmol/l. Lignocaine decreases the duration of action potential. Thus it 
indirectly decreases the production of triggered potentials. However, this effect is 
inconsistent with a reported success rate of only 50%. 
  There is an inverse relation between the heart rate and the repolarisation 
duration. So magnesium with or without potassium should be associated with 
increase in the heart rate. Magnesium is relatively safe. It is simple intervention in 
TdP.  It is the first line drug therapy in TdP. 
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MAGNESIUM AND HYPERTENSION 
Magnesium has a vasodilatory effect, patho-physiological role in 
systemic hypertension
39-41
. According to various studies done there was an 
inverse relationship between blood pressure and magnesium. Hypomagnesemia 
has been associated with left ventricular hypertrophy and high blood pressure. 
Some of the investigators have shown that   patients with hypomagnesemia may 
need higher doses of anti hypertensive drugs for treatment. 
 However, there was a considerable research done and the exact 
underlying cause of this remain unclear for decreased magnesium levels  in 
patients with  hypertension. It can be taken in a way that low magnesium in diet 
or disturbance in metabolism of magnesium can cause vasospasm  and 
endothelial damage .Combined effect of hypomagnesemia with stress and 
catecholamine secretion which enhances the entry of calcium into vascular 
smooth muscle cells which again leads to coronary spasm and increased 
arteriolar tone. 
Increased blood pressure, its complication may be due to smooth muscle 
contraction and enhanced calcium influx into the cell.  
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Magnesium is also known as natural calcium antagonist and magnesium 
acts on calcium channel present in vascular smooth muscle which leads to 
lowers the arterial blood pressure properties. Which again results to reduce the 
peripheral and also cerebral vascular resistance.   Competitive inhibition of 
calcium binding and its influx exerts vasodilatation. In various animal studies 
has been proved that vasodilatation properties of magnesium, these studies are 
tells that we can reduce the blood pressure and vascular tone modification by 
the way of minor change in magnesium concentrations. 
MAGNESIUM AND DM 
Hypomagnesemia in DM caused by 
1. Intake of diet was reduced in case of diabetics due to diabetic 
gastroparesis, esophageal dysfunction.    
2. Autonomic dysfunction which leads to diarrhea causing excessive 
magnesium loss. 
3. Increased renal magnesium loss  which due to excessive filtered load and 
filtration osmotic diuresis due to glucosuria ,increased volume 
replacement also due to diabetic ketoacidosis, microalbuminuria, overt 
proteinuria and by hypoalbuminemia, 
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4. Reduced renal reabsorption because of phosphate , potassium depletion 
insulin deficiency, diabetic ketoacidosis,  
 
HYPOMAGNESEMIA AND ITS OUTCOMES IN TYPE 2 DM 
 
There is considerable evidence to suggest that hypomagnesemia may 
adversely affect various aspects of cellular physiology. Available data suggest 
that low Mg levels may enhance endothelial cell dysfunction and 
thrombogenesis by the way of enhanced platelet aggregation and vascular 
calcifications. 
Hypomagnesemia may also induce proinflammatory and profibrogenic 
response, augment the vasoconstriction and hypertension and stimulation of 
aldosterone, reduce the protective enzymes against oxidative stress. Hence 
magnesium plays a role in DNA synthesis and repair and its deficiency may 
interrupt the regulation of apoptosis and normal cell growth 
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CADIOVASCULAR: 
Resnick et al showed in a study magnesium concentration was low in 
both hypertension and diabetic individuals
42
.Risk in Communities (ARIC) 
Study, a multicenter, prospective cohort study was done among men with 
diabetes showed that there was an inverse association between risk for coronary 
heart disease and serum magnesium. 
 
DIABETIC RETINOPATHY: 
 Two cross-sectional studies shown that hypomagnesemia has a link with 
diabetic retinopathy.
43-44 
 
NEPHROPATHY 
Corsonello et al was found that serum ionized Mg was low in micro 
albuminuric and overt proteinuria in patients with diabetes compared with non 
micro albuminuric group. Also hypomagnesemia associated with faster rate of 
renal function deterioration according to reports in recent retrospective study. 
 There are study which shows hypomagnesemia is related to dyslipidemia 
and neurologic abnormalities. Lots of efforts are needed to minimize 
hypomagnesemia in diabetic patients because which is linked with micro and 
macrovascular complications 
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INSULIN DEFICIENCY AND / RESISTANCE 
Due to anti magnesiuric effects of insulin in both the TAL and the DCT, 
renal magnesium wasting may be exacerbated by insulin defeciency or 
resistance 
46 
 
 
Possible underlying mechanisms 
The mechanism of worsening of existing diabetes in patients having 
hypomagnesemia is not clear. It has been suggested that magnesium regulates 
cellular glucose metabolism, it plays a significant role as a cofactor for various 
enzymes and which also acts as a second messenger for insulin. 
 
It was also discovered that insulin increases intracellular magnesium uptake 
and thereby mediates diverse effects of insulin. Hypomagnesemia may cause 
disturbed cellular glucose transport, decreased pancreatic insulin release, defective 
post-receptor insulin signalling and changes in insulin– receptor interactions and 
thereby increase insulin resistance. 
 
Therapeutic considerations 
Two studies studied the effect of magnesium supplementation 
in non-diabetic insulin-resistant individuals: 
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  One study in 60 non-diabetic hypomagnesemic individuals shows in a 
double-blind, randomized trial over 3 months, that daily supplementation of 300 
mg (12.3mmol) magnesium greatly enhanced insulin sensitivity. This information 
was proved in a recent placebo-controlled randomized trial in 52 normo 
magnesemic, but overweight and insulin-resistant individuals, in whom Mg 
administration 
 
Over 6 months led to a great improvement of fasting plasma glucose and 
insulin sensitivity indices as against the placebo. Whether known T2DM patients 
benefit from the supplementation of magnesium was studied in a meta-analysis of 
nine randomized-controlled trials enrolling 370 participants. Dosage, indications 
and inclusion criteria differed. 
Number of individuals in the single studies were relatively less and the 
outcome variable. Oral magnesium administration at a dose of 15mmol/day used as 
supplement therapy for 4–16 weeks resulted in of lowering fasting glucose levels, 
but only slightly lowered HbA1C and increasing HDL-C
45
. One study, studying the 
effect on lipid profiles that was not studied in the above meta analysis, as a 
combination of magnesium and vitamin C and E was used, resulted in an increase 
in HDL-C and Apo A1 but no other variations in lipids including triglycerides. 
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       Magnesium supplements singly or in combination with other supplements 
(i.e. Zinc, vitamin E, C and B complex) have also been shown to be useful in cases 
of diabetic neuropathy and depression. 
 
IN DIURETIC USAGE 
Magnesiuria may be caused by two types of diuretics; this effect was 
lower in thiazides compared to loop diuretics. Which may be due to the site of 
action of diuretics, thiazides acts in DCT which have lower amount of 
intraluminal Mg also inhibit NaCl co-transporter which induce the 
hyperpolarization of the DCT plasma membrane and there is a more favorable 
transmembrane electrical gradient for Mg reabsorption, in spite of that chronic 
thiazide usage inhibits TRMP6 channels leading to hypomagnesemia. 
 
It also mimics Gitelman’s syndrome as it also inhibits Na
+
Cl
- 
cotransporter leading to sodium excretion. With help of this observation a 
experiment was done in mice by giving chronic thiazide therapy which showed 
reduced TRPM6 expression and increased magnesiuria 
 
 
 
 
 
 
 
 
53 
 
MAGNESIUM IN DIABETIC KETOACIDOSIS 
Major magnesium loss was noted in case of diabetic ketoacidosis in early 
treatment stage. This loss is due to insulin therapy and fluid therapy, phosphate 
replacement .In patients with diabetic ketoacidosis phosphate replacement 
therapy. 
 
BUTLER and ASSOCIATES have suggest the inclusion of magnesium 
replacement in the management of diabetic ketoacidosis. However, the 
AMERICAN DIABETIC ASSOCIATION recommendation is to supplement 
magnesium only in patients with documented hypomagnesemia.
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 MAGNESIUM IN METABOLIC ACIDOSIS: 
 Metabolic acidosis plays a role in enhancing serum ionized Mg 
concentration as well as ultrafiltrable Mg load for renal excretion and increase 
protonation of the Mg channel in the DCT also inhibit the Mg entry into cell, so 
that hypomagnesemia can occurs. 
NIJENHUIS et al found that reduced expression of TRPM6 in case of 
induced chronic metabolic acidosis in mice.  
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MAGNESIUM AND METABOLIC SYNDROME: 
 
The triad of hypertension, obesity and impaired glucose tolerance 
constitute metabolic syndrome. Magnesium deficiency increases insulin 
resistance in patients with metabolic syndrome as well as type 2 DM
47,48
. 
Hypomagnesemia alters glucose entry into the cells. This results in impaired 
activity of tyrosine kinase and modification of intracellular signaling and 
processing. There was a prospective study which showed that there is inverse 
relationship between intake of magnesium and incidence of metabolic 
syndrome. 
 
  MAGNESIUM AND ALCOHOL 
Hypomagnesemia is a common phenomenon in chronic alcoholics. 
Rising alcohol levels in the blood causes increased urinary excretion of 
magnesium acutely
49
. DUNN and WALSER showed in their study that if the 
alcoholic patients are taking low magnesium diet, urinary magnesium excretion 
was not high. Malnutrition  may be the cause for  depletion of magnesium  in 
alcoholics . Hypophophatemia is found to be associated with hypomagnesemia 
in alcoholics. There is a possibility that depletion of magnesium is secondary to 
decrease in phosphate levels.  
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ALCOHOL WITHDRAWAL 
 As already stated that alcoholism leads to hypomagnesemia by increased 
loss of magnesium in urine, malnutrition, gastrointestinal magnesium loss, 
deficiency of phosphate and deficiency of vitamin D. There are animal studies 
to support the role of magnesium therapy in alcohol withdrawal. There is only 
one randomized control trial, in humans where magnesium supplementation in 
alcohol withdrawal was studied. But it failed to demonstrate significant benefit. 
  The American Society of Addiction Medicine on the pharmacological 
management of alcohol withdrawal practice guidelines  says there is no data 
that severity of withdrawal or incidence of delirium or occurrence of seizures 
were reduced by magnesium  supplementation. 
 
ACUTE CEREBRAL ISCHEMIA 
Magnesium enhances cerebral blood flow, in animal studies shows that 
association of reduced levels of extracellular magnesium   and cerebral 
vasospasm
50-53
.Mg buffers intracellular calcium and counteracts calcium actions 
in voltage gated channels leading to blocking of NMDA receptor and 
regeneration of ATP. 
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Many epidemiologic studies was done among those people consuming 
magnesium rich diet which showed a decrease in stroke rates and death from 
stroke which initiates  the  interest in the use of magnesium which was followed 
by number of animal studies was done. This study showed that experimentally 
induced cerebral infarctions size reduced by magnesium supplementation.  
A study was done in rats with middle cerebral artery occlusion by LEE 
and coworkers. It showed that there was decreased demand for energy and 
prevention of energy depletion occurs when administration of magnesium and 
mexilitine, a sodium channel blocker separately.
51 
Schmid-Elsaesser and colleagues induced cerebral ischemia in rats. They 
found that administration of magnesium and the antioxidant-tirilazad decreased 
the infarct volume by 25% when given separately
53
.In combination, these 
agents decrease the infarct volume by 59%. They also found that with 
hypothermia these agents were able to completely abolish the cortical infarcts. 
It is found in   studies that there is a significant correlation between low 
cerebrospinal fluid Magnesium concentrations and size of the infarct and 
intensity of residual neurologic deficit. 
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MIGRAINE  
Magnesium does have role in migraine treatment as evidenced by the 
following reasons. 
1. Serotonin receptors found to be altered   ionized magnesium. 
2. Improvement in cerebral vasospasm is seen by a greater ratio of ionized 
calcium and ionized magnesium. 
There are studies which say magnesium can help in prophylaxis.  There are 
two studies to suggest that magnesium has a role in the management of acute 
attack of migraine. MAUSKOP et al was successful in showing that there was 
relief of headache within 15 minutes of administration of intravenous magnesium 
in 32 of 40 patients studied who had   migraine, cluster headache, or tension 
headache. 
 In 18 this lasted for one day and low levels of serum magnesium was found 
in 16 of them. DEMIRKAYA et al showed there was reduction of headache in 13 
of 15 patients with migraine after administration of intravenous magnesium. 
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PREECLAMPSIA AND ECLAMPSIA 
The neuromuscular transmission is found to be altered by magnesium. 
Magnesium competes with calcium entry into the presynaptic endings.
54
 It 
reduces the effect of acetylcholine on post synaptic receptors on muscles. 
Magnesium also raises the threshold for axonal excitation. Thus it has 
depressant effect on the synapses in the nervous system. Magnesium has been 
found to potentiate the action of non depolarizing neuromuscular blockers. 
Preeclampsia complicates 7% of the pregnancies. When patients with 
preeclampsia develop seizures, the condition is termed as eclampsia. Several 
mechanisms are involved in prevention of seizure activity by magnesium. These 
include increase in cerebral flow, stabilization of neuronal membrane, 
prevention of vasospasm in cerebrum and anti platelet action
54-57
 .In prichards 
regimen, magnesium sulphate is given as  4g iv stat followed by 2-3g/hr 
infusion to maintain a serum concentration of 5-7 mg/dl. Mg toxicity has to be 
monitored. This toxicity is manifested by the loss of deep tendon reflexes, 
muscular weakness leading to respiratory failure, complete heart block and 
cardiac arrest. 
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ASTHMA 
 Okayama and colleague study has shown remarkable improvement in 
FEV1 of asthmatics during acute exacerbation by administration of 
magnesium
58-60
. Rapid administration of Mg as infusion has decreased need for 
intubation due to reversal of bronchospasm. 
Inhaled Mg has decreased bronchoconstrictor effect of metabisulfides 
leading to bronchodilatation. The evidence that Mg is a bronchodilator is 
convincing and adequate to put forth its use as a drug in refractory asthma. 
Magnesium causes changes in extracellular calcium influx leading to 
changes in   intracellular phosphorylation reactions. It interferes with mast cell 
degranulation and suppresses the neutrophilic burst which causes inflammatory 
bronchoconstriction. The mast cell degranulation is stimulated by increasing ICF 
calcium levels which is counteracted by magnesium. 
The bronchodilatory effect of salbutamol is improved by use of Mg. 
Magnesium decreases histamine induced bronchospasm thereby relieving the 
symptoms. 
SKOBELOFF et al showed that administration of magnesium in cases with 
severe exacerbation of bronchial asthma in emergency room showed remarkable 
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improvement in peak expiratory flow rate thereby increasing the number of 
discharge from emergency room. Similar results were obtained from Cochrane 
systemic review conducted in 1999which substantiated use of magnesium sulphate 
in acute severe asthma.  
Use of magnesium as a single drug in nebulization is still experimental but 
isotonic magnesium with beta agonist has shown fruitful results. MOLLOY et al in 
a study that magnesium supplementation showed significant effect in respiratory 
muscle weakness in cases who had hypomagnesemia. 
MAGNESIUM AND SNAKE BITE 
Snake venom contains toxic and nontoxic substances which damage the 
renal tubules. 75% of magnesium reabsorbed into renal tubules, 3-5% excreted 
in urine, hence renal tubular damage may increases the renal Mg loss leads to 
magnesium deficiency. 
Hypoxia or anoxia caused by snake venom increases the intracellular Mg 
concentration due to shift of extracellular Mg into intracellular fluid also 
induces magnesium deficiency. 
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EFFECTS OF MAGNESIUM IN CALCIUM METABOLISM 
Calcium metabolism has been found to altered by magnesium depletion 
in various studies done in humans and animals.
63
 The lower levels of calcium 
changes internal mechanisms which controls calcium levels leaving external 
calcium balance unchanged. Parathyroid hormone secretion is stimulated by 
low magnesium and low calcium levels. Changes in either of these cations has 
significant effect on PTH secretion. Thereby simultaneous increase in one 
cation with decreased levels of other cation leaves the PTH levels unchanged 
.In in vitro studies the combined concentration of calcium and magnesium and 
parathyroid release showed a first order relationship. 
 In acute magnesium depletion magnesium has a direct effect on PTH, 
whereas in chronic Mg depletion parathyroid function appears to affected in 
opposite direction. In ANAST and colleagues, MENNES and associates studies 
showed that intravenous administration of magnesium in hypomagnesemic 
patients has increased the PTH levels. Hypomagnesemia induced hypocalcemia 
also result from skeletal resistance to PTH according to various studies. In vivo 
studies done in hypomagnesemic dogs and rats and monkeys found that normal 
calcemic response to PTH. 
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 Studies in human performed by Estep and associates in hypomagnesemic 
alcoholic patients, MULDOWNEY and coworkers in magnesium depletion 
secondary to malabsorption syndrome and Woodard and colleagues in patients 
with diarrhoea showed an impaired calcemic response from PTH. CHASE and 
SLATOPOLSKY found a normal calcemic response from PTH in two 
hypocalcemic hypomagnesemic adults. 
 There are several factors that lead to low calcium levels due to depletion 
of magnesium. As well loss of Mg ion from the bone leads to deposition of 
calcium rendering the bone resistant to PTH action. In early course the secretion 
of PTH is decreased followed by resistant to PTH later. Thus both the levels of 
Mg and duration of hypomagnesemia lead to difference in response of bone to 
PTH. 
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EFFECTS OF MAGNESIUM DEPLETION ON POTASSIUM AND 
OTHER INTRACELLULAR SUBSTANCES 
 In various studies conducted, patients with hypokalemia are also 
hypomagnesemic
61-62
. Studies conducted on patients with alcohol and diabetic 
ketoacidosis reported coexistence of hypomagnesemia and hypokalemia more 
commonly.  
 
Depletion of potassium were of two types, 
1. Combined intracellular and extra cellular depletion. 
2. Intracellular depletion alone .Potassium repletion is also 
accomplished with administration of magnesium. 
 
 Diuretic therapy often led to refractory potassium depletion which proved 
repletion of magnesium is necessary to normalize potassium. This was 
supported by studies conducted on animals in which myocardial depletion of 
potassium was prevented by infusion of magnesium. This is due to stimulatory 
effect on Na K ATP ase pump. 
There is also direct effect of magnesium on sarcolemmal potassium 
channels due to compete with calcium ion. In other hand aldosterone is 
increased in kaliuresis due to magnesium depletion. The potassium rich diet 
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leads to more magnesium retention and in many conditions it is not possible to 
increase either of these ions without replenishing the other one there are reports 
in which supplementation with potassium induced tetany there are reports in 
which supplementation with potassium induced tetany as the serum calcium and 
magnesium values dropped due to rise in serum potassium. 
This was reversed by supplementation with magnesium ions thereby 
explaining the fact decreased magnesium resulted in tetany due to coexistence 
of hypocalcemia occurring as a result of potassium supplementation. 
Furthermore, magnesium depletion led to depletion of muscle phosphorus as it 
caused rhabdomyolysis due to magnesium dependent phosphate depletion. 
 
MAGNESIUM IN DIGITALIS TOXICITY: 
 In digitalis toxicity, digitalis acts on Na
+
K
+
ATP ase pump inhibiting its 
action leading to in the rhythm disturbances .The transmembrane potassium 
gradient produced in digitalis toxicity can be managed effectively by using 
magnesium which is cofactor in regulating ion transport system 
 In case of severe digitalis toxicity, Fab antibodies  is the treatment of choice  
but Mg is a effective temporary  measure in management of severe digitalis 
toxicity. Magnesium use has been proved to be safe, cost effective and easy to use. 
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METHODS AND MATERIALS 
STUDY GROUP :  Patients admitted in intensive 
  medical care unit at KMCH who 
  satisfied inclusion criteria                    
STUDY DESIGN    :  Cross-Sectional study 
PLACE OF STUDY  :   Intensive medical care unit      
  Kilpauk Medical College and  
  Hospital, Chennai–10 
DURATION OF STUDY         :  April 2014 to September  2014  
CONFLICT OF INTEREST   :    Nil 
SAMPLE SIZE           :    100 
CONSENT     : Patients taken into the study only  
    after getting a written informed  
    consent. 
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COLLABORATING DEPARTMENTS:  
Department of General Medicine (Intensive medical care unit), and 
Department of Biochemistry, 
Kilpauk medical college and hospital, Chennai-10.              
INCLUSION CRITERIA 
These includes patients admitted in ICU with 
•     Cardiac Failure  
•     Respiratory Failure  
•     Poisoning  
•     Snake bite  
•     Sepsis  
•     Cerebro vascular accident  
•     Status epilepticus  
•     Diabetic Keto Acidosis  
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EXCLUSION CRITERIA:  
• Patients who had previously documented Hypomagnesemia. 
• Patients with Renal failure and those who have magnesium more than 
2.5mg/dl. 
• Patients who were on Magnesium supplementation and Blood 
Transfusion. 
 
METHODOLOGY 
• The data of each patient were collected in the specific proforma which 
included detailed history and thorough physical examination. 
• Serum Magnesium estimated within 24 hours of admission. 
• CBC, RFT, LFT, Urine routine, ECG, ECHO. 
• CXR PA view, CT BRAIN plain.ABG analysis were done for patients 
appropriate to their clinical condition. 
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 The outcome of the patient was analysed by. 
1. Length of stay in ICU 
2. Need for ventilatory support,  
3. Duration of ventilatory support 
    4. Survival/death 
5. APACHE II score 
METHOD OF SERUM MAGNESIUM ESTIMATION: 
Estimated at Biochemistry Lab in Kilpauk   medical college and hospital. 
Method – Calmagite Test. 
Reagent – Calmagite  
Reference range for Magnesium: 1.7- 2.5 mg/dl. 
 
CALMAGITE METHOD: 
In an alkaline medium Magnesium binds with calmagite to form a red 
coloured complex. Interference of proteins and calcium is removed by the 
addition of detergents and specific chelating agents. The sample containing 
amount of magnesium is directly proportional to intensity of the colour. 
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CONTENTS: 
L1: Buffer Reagent                
L2: Colour Reagent                 
S:    Magnesium Standard  
 
WORKING REAGENT: 
For larger assays series a working reagent may be prepared by mixing 
equal volumes of L1 and L2. This reagent is stable at 2-8 deg C for atleast one 
month. 
 
PROCEDURE: 
Wavelength/filter      : 510 nm/green 
Temperature              : R.T 
Light path                  : 1 cm 
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CALCULATIONS:  Magnesium in mEq/L = Abs.T/Abs.S x 2 
   
This procedure is linear upto 10mEq/L.If values exceed this limit, dilute 
the sample with distilled water and repeat the assay. Calculate the value using 
an appropriate dilution factor. 
PRECAUTIONS:  
All glassware being used for the test should first be rinsed with 1% or 0.1 
N HCl and then with good quality de ionised water before use. 
Chelating agents such as EDTA, OXALATE and CITRATE present even 
in traces, prevent the formation of the colour complex, hence necessary care 
should be taken during the assay. RBC’s have double the magnesium content 
compared to serum and hence hemolysed samples should not be used. 
ADDITION SEQUENCE B           S                 T 
Buffer Reagent 0.5        0.5            0.5 
Colour Reagent 0.5         0.5          0.5 
Distilled water 0.01        -                - 
Magnesium Standard -            0.01            - 
Sample -              -            0.01 
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STATISTICAL ANALYSIS 
STATISTICAL TOOL:      
  Data was analysed statistically by Mean, Standard Deviation, Chisquare 
test and linear and linear regression. Proportions found using softwares, p<0.05 
is considered statistically significant. 
  Independent sample- t test is used to calculate the mean values of the 
parameters.  In this study 95% confidence interval was employed. Tables and 
Graphs were generated by using Microsoft word and Excel sheet. 
Correlation between serum magnesium levels, mortality, need for 
ventilatory support, duration of ventilatory support, stay in ICU, APACHE 
score, serum sodium levels, serum potassium levels and serum calcium levels 
are assessed by chi square test.  
SPSS (software package used for statistical analysis) was used for all 
statistical analysis. 
SAMPLE SIZE  
It was calculated using the formula    4pq/I
2
 
    p=52,q=48 , I 
2
=20% of p 
    4×52×48/ (10.4)
2
=92.307 approx 95  
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RESULTS: 
In our study we analysed 100 patients, in that 53 persons are  
hypomagnesemics, 47 persons  are  normomagnesemics 
Table 1 AGE DISTRIBUTION AMONG THE STUDY GROUP 
Age in years No. of cases percentage 
<20 5 5 
21-30 14 14 
31-40 20 20 
41-50 22 22 
51-60 14 14 
61-70 21 21 
>70 4 4 
Total 100 100 
 
The minimum age of the patient is <20.The maximum age is >70. Among 
the 100 patients, 5% are in the age group of <20. 14% are in the age group of 21-
30. 20% are in the age group of 31-40. 22% are in the age group of 41-50. 14% are 
in the age group of 51-60. 21% are in the age group of 61-70. 4% are in the age 
group of >70. 
 Figure 1 AGE DISTRIBUTION AMONG STUDY GROUP
Table 2 MEAN and STANDARD DEVIATION VALUES
  
AGE 
S Mg 
S Na 
S K 
S Ca 
TC 
APACHE II
Stay_in_ICU
 
5
14
0
5
10
15
20
25
<20 21 - 30
Age distribution
73 
Mean Std. Deviation 
46.96 16.555 
1.6660 .61401 
136.7600 8.57424 
3.7830 .65921 
9.7360 1.09152 
11248.40 4037.585 
 14.65 7.599 
 3.63 1.739 
20
22
14
21
4
31 - 40 41 - 50 51 - 60 61 - 70 >= 70
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Table 3 GENDER DISTRIBUTION AMONG STUDY POPULATION 
 
 
 
 
 
 
Among the 100 patients, 57 were males and 43 were females i.e.57% were 
males and 43% were females. 
Figure 2 GENDER DISTRIBUTION AMONG STUDY GROUP 
 
 
 
Male
57%
Female
43%
0%
sex distribution 
Gender  Frequency Percentage 
Male 57 57.0 
Female 43 43.0 
Total 100 100.0 
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Yes
45%
No
55%
0%
H/O DM Percentage
Table 4 DISTRIBUTION OF DIABETES MELLITUS AMONG STUDY 
GROUP 
H/o DM Frequency Percentage 
Yes 45 45.0 
No 55 55.0 
Total 100 100.0 
 
Of the 100 patients, 45 are diabetic i.e. 45% are   diabetic.  
Figure 3 DISTRIBUTION OF DIABETES MELLITUS AMONG STUDY 
GROUP 
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Yes
27%
No
73%
H/O SHT Percentage
Table 5 HYPERTENSION AMONG STUDY GROUP 
H/o HT Frequency Percentage 
Yes 
27 27.0 
No 
73 73.0 
Total 
100 100.0 
 
Of the 100 patients, 27 are hypertensive i.e. 27% are hypertensive. 
 
Figure 4 HYPERTENSION AMONG STUDY POPULATION 
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Yes
19%
No
81%
 
Table 6 ALCOHOLISM AMONG STUDY POPULATION 
H/o  ALCOHOL Frequency  Percentage  
Yes  19 19.0 
No  81 81.0 
Total  100 100.0 
 
Of the 100 patients, 19 are alcoholic i.e. 19% are alcoholic. 
Figure 5ALCOHOLISM AMONG STUDY POPULATION 
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Table 7  CASES AMONG   STUDY POPULATION 
                          CASES Frequency Percentage 
CVA 15 15.0 
Heart failure 12 12.0 
Poisoning 15 15.0 
Respiratory failure 10 10.0 
Sepsis 30 30.0 
Snake bite 6 6.0 
Status epilepticus 5 5.0 
DKA 7 7.0 
Total 100 100.0 
Of the 100 patients, 15% had CVA, 12 % had heart failure, 15% had 
poisoning , 10% had respiratory failure, 30% had sepsis, 6% had snake bite, 5% 
had status epilepticus, and 7% had DKA . 
Figure 6 CASES AMONG STUDY POPULATION 
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Table 8 DURATION OF HOSPITAL STAY AMONG POPULATION 
Duration of stay in 
days 
Frequency Percentage 
1 7 7.0 
2 23 23.0 
3 20 20.0 
4 17 17.0 
5 17 17.0 
6 12 12.0 
8 2 2.0 
9 1 1.0 
Total 100 100.0 
 
It was noted that 7% of the patients stayed in the ICU for 1 day, 23% for 2 
days, 20% for 3 days, 17% for 4 days, 17% for 5 days, 12% for 6 days, 2% for 8 
days and 1% for 9 days. 
 
 
80 
 
24%
76%
Need for Ventilatory support
Yes No
 
Table 9 REQUIREMENT OF VENTILATORY SUPPORT AMONG STUDY 
POPULATION 
Need for ventilator 
support 
Frequency Percentage 
Yes 24 24.0 
No 76 76.0 
Total 100 100.0 
 
Of the 100 patients, 24 % required ventilatory support. 
Figure 7 VENTILATORY SUPPORT REQIUREMENT AMONG STUDY 
GROUP 
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Table 10 DURATION OF THE VENTILATORY SUPPORT AMONG THE 
STUDY POPULATION 
 
 
  During the study it was noted that 16.7% of the patients required 
ventilator support for 1 day, 25% for 2 days, 33.3% for 3 days, 20.8% for 4 days 
and 4.2% for 5 days. 
 
 
Duration of 
ventilatory support in 
days 
Frequency Percentage 
1 4 16.7 
2 6 25.0 
3 8 33.3 
4 5 20.8 
5 1 4.2 
 
Total 
24 100 
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20%
80%
MORTALITY
Yes No
 
 
Table 11 MORTALITY RATES IN THE STUDY POPULATION 
Mortality Frequency Percentage 
Yes 20 20.0 
No 80 80.0 
Total 100 100.0 
 
Among 100 population, 20% are alive ,80% are died persons  
 
Figure 8 MORTALITY AMONG STUDY POPULATION 
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53%
47%
Hypomagnesemia Percentage
Hypomagnesia normal
Table 12HYPOMAGNESIMIA AMONG STUDY POPULATION 
Hypomagnesemia Frequency Percentage 
Yes 53 53.0 
No 47 47.0 
Total 100 100.0 
 
Among the 100 poulation, 53 patients had hypomagnesemia 
 
Figure 9 HYPOMAGNESIMIA AMONG STUDY POPULATION 
 
 
 
 
 
 
 
 Table 13 HYPONATREMIA AMONG STUDY POPULATION
Hyponatremia 
Yes  
No  
Total  
 
Among 100 population 33% of patients have hyponatremia, 67%
have normal level 
Figure 10 HYPONATREMIA AMONG STUDY GROUP
 
 
 
 
 
 
 
 
84 
33%
67%
Hyponatremia Normal
Frequency Percentage 
33 33.0 
67 67.0 
100 100.0 
 
 of patients 
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27%
73%
Hypokalemia Percentage
Hypokalemia normal
Table 14 HYPOKALEMIA AMONG STUDY POPULATION 
Hypokalemia Frequency Percentage 
Yes 27 27.0 
No 73 73.0 
Total 100 100.0 
 
Of 100 population 27%  are hypokalemic, 73% are normokalemic 
 
Figure 11 HYPOKALEMIA AMONG STUDY POPULATION 
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17%
83%
Hypocalcemia Normal
Table 15 HYPOCALCEMIA AMONG STUDY GROUP 
Hypocalcemia Frequency Percentage 
Yes  17 17.0 
No  83 83.0 
Total  100 100.0 
 
Of 100 population 17% had hypocalcemia, 83% had normal calcium levels 
Figure 12 HYPOCALCEMIA AMONG STUDY GROUP 
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Table 16 APACHE II IN STUDY POPULATION 
APACHE II 
SCORE 
Frequency Percentage 
< 4 7 7.0 
5 - 9 24 24.0 
10 - 14 19 19.0 
15 - 19 29 29.0 
20 - 24 10 10.0 
25 - 29 6 6.0 
30 - 34 4 4.0 
>35 1 1.0 
Total 100 100.0 
 
Among 100 population  7% of patients had APACHE SCORE of 4 
                                     24% of patients had APACHE SCORE of 5-9 
                                    19% of patients had APACHE SCORE of 10-14 
                                       29% of patients had APACHE SCORE of 15-19 
                                       10 % of patients had APACHE SCORE of 20-24 
                                      6% of patients had APACHE SCORE of 25-29 
                                        4% of patients had APACHE SCORE of 30-34 
                                     1% of patients had APACHE SCORE of > 35  
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Figure 13 APACHE II IN STUDY GROUP 
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Table 17 STATISTICAL VALUES FOR VARIOUS PARAMETERS 
Parameters Associated 
hypomagnes
emia 
Normal 
magnesium 
Chi- square 
value 
P value 
DM  25 20 .215 .643 
HT 17 10 1.474
a
 .225 
ALC 9 10 .299
a
 .585 
Hyponatremia  24 9 7.695
a
 .006 
Hypokalemia 21 6 9.116
a
 .003 
Hypocalcemia 13 4 4.529
a
 .033 
Need for ventilator  19 5 8.680
a
 .003 
Mortality  16 4 7.316
a
 .007 
Duration of ventilator 19 5 4.547 0.337 
APACHE-2 score   6.989 0.000 
Stay in ICU   19.896 0.011 
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Table 18 MAGNESIUM LEVELS AMONG VARIOUS AGE GROUP 
Age_Group          MAGNESIUM Total 
 Hypomagnesemia normal  
<20 3 2 5 
21 - 30 11 3 14 
31 - 40 9 11 20 
41 - 50 10 12 22 
51 - 60 5 9 14 
61 - 70 11 10 21 
> 70 4 0 4 
Total 53 47 100 
 
In our study we found that maximum number of hypomagnesemia and 
normomagnesemia were in the age group between 41-50 years. 
Minimum age:< 20 
Maximum age:> 70 
Mean age: 46.51 
SD: 18.117 
There was no correlation between the age distribution and the Mg levels. 
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Figure 14 MAGNESIUM LEVELS AMONG VARIOUS AGE GROUPS OF 
THE STUDY POPULATION 
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Table 18 GENDERWISE DISTRIBUTION OF MAGNESIUM VALUES
GENDER MAGNESIUM LEVEL
 Hypomagnesemia
Male 
Female 
Total 
 
Among 100 population,
found that 32 men had hypomagnesemia and 21 female had hypomagnesemia.
There was no correlation between sex 
Figure 15 GENDERWISE DISTRIBUTION OF MAGNESIUM VALUES
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Nrl Mg
Low Mg
FEMALE
Nrl Mg
Low Mg
 Total 
 Normal  
32 25 57 
21 22 43 
53 47 100 
 in which 57 were male and 43 were female,
distribution and Mg levels. 
 
 it was 
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Table 19 MAGNESIUM VALUES AMONG THE VARIOUS SUBGROUPS 
OF STUDY POPULATION 
DISEASES MAGNESIUM Total 
 Hypomagnesemia Normal  
CVA 9 6 15 
Heart failure 6 6 12 
Poisoning 7 8 15 
Respiratory faiure 5 5 10 
Sepsis 16 14 30 
Snake bite 3 3 6 
Status epilepticus 3 2 5 
DKA 4 3 7 
Total 53 47 100 
 
Among 100 population, magnesium levels was found to be low in 16 cases 
of sepsis ,9 cases of CVA,7 cases of poisoning, ,6 cases of heart failure ,5 cases of 
respiratory failure, 4 cases of DKA , 3 cases of status epilepticus and 3 cases of 
snake bite, in this sepsis had more percentage of hypomagnesemic levels. 
 Figure 16 MAGNESIUM VALUES AMONG VARIOUS SUBGROUPS OF 
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Table 20 ASSOCIATION OF MAGNESIUM LVELS AND DIABETES 
MELLITUS 
 Magnesium Total Pearson Chi-
Square value 
P value 
Hypomagnesemia normal 
H/O 
DM 
Yes 25 20 45 .215 
 
 
.643 
 No 28 27 55 
Total 53 47 100 
 
Among the cases, 45 patients had DM, in that 25 patients had 
hypomagnesemia and 20 patients had normal level of magnesium. P value is 
0.643 which is >0.05 so it is not correlated significantly 
Figure 17 ASSOCIATION OF MAGNESIUM LEVELS AND DIABETES 
MELLITUS 
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Table 21 ASSOCIATION OF MAGNESIUM LEVELS AND 
HYPERTENSION 
 
Among 100 population, 27% were hypertensives in which 17 patients 
were found to have hypomagnesemia. Mean value 1.5741.SD-0.49892.P value 
0.225 which is > 0.05, so it is not statistically significant 
Figure 18 ASSOCIATION OF MAGNESIUM LEVELS AND 
HYPERTENSION 
 
 
 
 
SHT MAGNESIUM TOTAL P-VALUE 
LOW NORMAL  
YES 17 10 27  
NO 36 37 73 0.225 
TOTAL 53 47 100  
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Figure 19 ASSOCIATION OF MAGNESIUM LEVELS AND ALCOHOL 
 
 
 
Of 100 patients 19 had alcohol, among that 9 persons had 
hypomagnesemia. Mean value 1.6632, SD 0.54079, P value 0.585 
which is > 0.05 so statistically not significant. 
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Table 22 ASSOCIATION OF HYPONATREMIA WITH MAGNESIUM 
LEVELS 
 
Figure 20 ASSOCIATION OF HYPONATEMIA AND MAGNESIUM 
LEVELS 
 
 
 
  
 
Of 100 patients 33 % were hyponatremic, 24 patients had hypomagnesemic. 
Mean 133.9623, SD 9.39305.P value 0.006 which is <0.05. so statistically 
significant. 
SODIUM MAGNESIUM Total 
 Hypomagnesemia Normal  
Hyponatremia 24 9 33 
Normal 29 38 67 
Total 53 47 100 
99 
 
0
5
10
15
20
25
30
35
40
45
hypokalemia normokalemia
Nrl Mg
Low Mg
 
Table 23 ASSOCIATION OF HYPOKALEMIA AND MAGNESIUM 
LEVLES 
POTASSIUM  MAGNESIUM Total 
 Hypomagnesemia normal  
Hypokalemia 21 6 27 
normal 32 41 73 
Total 53 47 100 
 
Of 100 patients ,27% had hypokalemia, in that 21 had hypokalemia . mean 
3.5434, SD 0.64077,P value 0.003 which is <0.05 so statistically significant 
Figure 21 ASSOCIATION OF HYPOKALEMIA AND MAGNESIUM 
LEVELS 
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Table 24 ASSOCIATION OF HYPOCALCEMIA AND MAGNESIUM 
LEVELS 
POTASSIUM  MAGNESIUM Total 
 Hypomagnesemia normal  
Hypocalcemia 13 4 17 
Normal 40 43 83 
Total 53 47 100 
 
Among 100 patients 17% were hypocalcemia.In that 13 had 
hypomagnesemia. Mean-9.4623       SD-1.11497      P value0.033 which is <0.05, 
so it is statistically significant 
Figure 22 ASSOCIATION OF HYPOCALCEMIA AND MAGNESIUM 
LEVELS 
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Table 25 ASSOCIATION OF MAGNESIUM LEVELS AND DURATION OF 
HOSPITAL STAY 
STAY IN ICU MAGNESIUM Total 
 Hypomagnesemia normal  
1 4 3 7 
2 6 17 23 
3 7 13 20 
4 10 7 17 
5 14 3 17 
6 8 4 12 
8 2 0 2 
9 1 0 1 
Total 53 47 100 
 
Among 100 study group mean range of stay in ICU 5, P value is 0.011 
which is less than 0.05 so it is statistically significant 
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Figure 23 ASSOCIATION OF MAGNESIUM LEVLES AND DURATION 
OF HOSPITAL STAY 
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Table 26 ASSOCIATION OF MAGNESIUM LEVELS AND 
VENTILATORY SUPPORT 
N for  VS MAGNESIUM Total 
 Hypomagnesemia normal  
Yes 19 5 24 
No 34 42 76 
Total 53 47 100 
 
24 among 100 patients need ventilatory support.in 24 patients 19 had 
hypomagnesemia. mean value 1.3000, P value 0.003 which is <0.05 so it is  
statistically significant 
Figure 24 ASSOCIATION OF MAGNESIUM LEVELS AND 
VENTILATORY SUPPORT 
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TABLE 27 ASSOCIATION OF MAGNESIUM LEVELS WITH DURATION 
OF VENTILATORY SUPPORT 
DURA.VS MAGNESIUM Total 
 Hypomagnesemia normal  
1 4 0 4 
2 4 2 6 
3 5 3 8 
4 5 0 5 
5 1 0 1 
Total 19 5 24 
 
Figure 25 ASSOCIATION OF MAGNESIUM LEVELS WITH DURATION 
OF VENTILATORY SUPPORT 
 
 
 
 
P value is 0.337 which is more than 0.05%. Thus there is no significant 
correlation with duration of ventilatory support. 
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Table 27 ASSOCIATION OF MAGNESIUM LEVELS WITH MORTALITY 
MORTALITY MAGNESIUM Total 
 Hypomagnesemia Normal  
Yes 16 4 20 
No 37 43 80 
Total 53 47 100 
 
Of 100 patients 20 died, out of which 16 had hypomagnesemia. P value 
0.007 which is <0.05 so it is statistically significant. 
Figure 26 ASSOCIATION OF MAGNESIUM LEVELS WITH 
MORTALITY 
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TABLE 28 ASSOCIATION OF MAGNESIUM LEVELS WITH APACHE II 
SCORE 
APACHE 
II 
HYPOMAGNESEMIA NORMOMAGNESEMIA 
>4 0 7 
5-9 3 21 
10-14 8 11 
15-19 25 4 
20-24 7 3 
25-29 6 0 
30-34 3 1 
>35 1 0 
Total 54 47 
 
 
Here the significant value is 0.000 which is less than 0.05 which is 
statistically significant. 
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Figure 27 ASSOCIATION OF MAGNESIUM LEVELS WITH  
APACHE II 
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Table 28 MEAN AND STANDARD DEVIATION FOR VARIOUS 
PARAMETERS AMONG STUDY POPULATION 
Group Statistics 
 Hypomagnese
mia 
N Mean Std. 
Deviation 
Std. Error 
Mean 
APACHE II Hypomagnesia 53 18.70 6.435 .884 
normal 47 10.09 6.107 .891 
TC Hypomagnesia 53 12512.08 4088.421 561.588 
normal 47 9823.40 3503.552 511.046 
S K Hypomagnesia 53 3.5434 .64077 .08802 
normal 47 4.0532 .57478 .08384 
S Ca Hypomagnesia 53 9.4623 1.11497 .15315 
normal 47 10.0447 .98749 .14404 
S Na Hypomagnesia 53 133.9623 9.39305 1.29023 
Normal 47 139.9149 6.26873 .91439 
 
From above results there was no correlation between serum magnesium and 
diabetes, hypertension, alcohol and duration of ventilator support. There was 
significant correlation between hypomagnesemia and stay in ICU, need for 
ventilator support, APACHE II score, Mortality, hyponatremia, hypokalemia and 
hypocalcemia. 
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DISCUSSION 
 Magnesium is a macro mineral. It acts as an essential for life. It is needed 
by the body in large amounts for many bodily function, like cardiac function, 
various enzymatic reactions, neuromuscular function, energy production, 
endocrine function, bone formation and growth, DNA repair and immunity. 
Magnesium levels are altered in many conditions like sepsis,inadequate 
magnesium intake,increased renal  loss in case of alcohol abuse, diuretics and 
digoxin  use, and gastrointestinal loss in case of vomiting, diarrhea, nasogastric 
tube loss, total parenteral nutrition, refeeding with glucose or aminoacids, insulin, 
metabolic acidosis and hypoalbuminemia , diabetics and acute pancreatitis 
Hypomagnesemia leads to muscular weakness, neuromuscular irritability, 
cardiac arrhythmia, electrolyte disturbances, seizures, and coma 
 So critically ill patients are at increased risk for hypomagnesemia and 
development of hypomagnesemia related mortality 
 In our study, a total of 100 patients were enlisted who were admitted in 
Intensive medical care unit 
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We tried to find out prevalence of low serum magnesium level in patients 
admitted in Intensive medical care unit and association between serum magnesium 
levels and length of stay, need for ventilator support, duration of ventilator support, 
APACHE SCORE II, mortality and most predominant illness associated with 
hypomagnesemia and associated other electrolyte disturbances 
In our study, among 100 patients, 53% patients had hypomagnesemia. 
Of 100 patients, 32 males had hypomagnesemia and 2 females had 
hypomagnesemia . 
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COMPARED WITH OTHER STUDIES 
1) Admission hypomagnesemia-impact on mortality or morbidity in critically 
ill patients done by SAFAVI M
65
 middle east J anesthesiol 2007 published 
in pubmed showed with hypomagnesemia at time of admission had poor 
prognosis           
2) Hypomagnesemia in critically ill medical patients done by LIMAYE CS, 
published in J association physicians India.2012 May showed patients with 
hypomagnesemia had higher mortality rate. 
3) A higher mortality rate was detected in hypomagnesemia patients as 
compared to normomagnesemia patients by CHERNOW et al, RUHTEZ et 
al and SAFAVI et al
64-65
 
In our study number of deaths in hypomagnesemia group was 16, which is 
significantly higher as compared to 4 patients in normomagnesemia 
(p<0.05) 
4) SAFAVI et al- in hypomagnesemia patients the length of ventilator support 
was increased
65. 
But in our study, the correlation between serum 
magnesium levels and duration of ventilator support was not significant. 
5) MUNOZ et al found that the requirement of ventilatory support is higher in 
patients with low magnesium levels. In our study also found that there was 
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significant correlation between  increased requirement of ventilatory 
support  and hypomagnesemia (p<o.o5) 
6) SOLIMAN et al studied that the days of stay in ICU is higher in patients 
with hypomagnesemia than in normomagnesemic patients. In our present 
study, hypomagnesemic patients had increased duration of stay in ICU than 
normomagnesemic,  which was significantly correlated with magnesium( p 
<0.05) 
7) WHANG et al and LIMAYE et al studies found hypomagnesemia 
associated with other electrolyte abnormalities, 42% cases with 
hypokalemia, with hypophophatemia 29%, with hyponatremia 27%, with 
hypocalcemia 22%. 
In  present study showed that there was significant correlation between 
hypomagnesemia  and hyponatremia  ,hypokalemia , hypocalcemia .(p 
<0.05) 
8) In a study done by SOLIMAN et al and LIMAYE et al had noted in chronic 
alcoholic there was one third of patients had hypomagnesemia and 
LIMAYE et study showed that 24% of alcoholics had hypomagnesemia. In 
LIMAYE et al study, noted diabetic patients more commonly associated 
with hypomagnesemia , 27% vs 17%. 
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In our present study there was no significant correlation between 
hypomagnesemia and alcoholics,(9 patients had hypomagnesemia in 
alcoholics vs 10 patients) and diabetes mellitus( P> 0.05) 
9) SOLIMAN et al study showed that there was significant correlation 
between hypomagnesemia and increased APACHE II 11.64 vs 9.5.  
In our study had noted that there was significant correlation  between  
hypomagnesemia and increased APACHE II. 
10) B.SONTIA, R.M.TOUYZ showed that there was correlation between 
hypertension and hypomagnesemia. 
But in our study , hypertension and hypomagnesemia association is not of 
much  significant. 
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CONCLUSION 
Hypomagnesemia is a common electrolyte imbalance in the critically ill 
medical patients. It is frequently associated with sepsis. It is associated with 
higher mortality and morbidity rate in                       critically ill patients. 
Also, hypomagnesemia is associated with increased length of stay and 
need for ventilatory support .In addition, hypomagnesemia is associated with 
increased APACHE score. It is associated with hyponatremia, hypokalemia, 
hypocalcemia. 
That is, low magnesium levels in patients admitted in intensive medical 
care unit may affect the prognosis of patients , hypomagnesemic patients have a 
guarded prognosis. 
Hence in a IMCU set up monitoring of serum magnesium levels along 
with other electrolytes has a very important therapeutic as well as prognostic 
implication. 
Correction of hypomagnesemia is very essential in the management of 
critically ill patients to have a better prognosis. 
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ANNEXURES 
PROFORMA 
NAME:                                                                                                  
AGE/SEX:                       I.P.NO.: 
OCCUPATION:                                                          DATE OF ADMISSION: 
ADDRESS: 
DIAGNOSIS:             DATE OF DISCHARGE: 
 
PAST HISTORY:  DIABETES MELLITUS/SYSTEMIC HYPERTENSION 
GENERAL EXAMINATION 
VITALS: 
BP:                 PR:                        RR:                SPO2 
SYSTEMIC EXAMINATION: 
CARDIO VASCULAR SYSTEM 
RESPIRATORY SYSTEM 
CENTRAL NERVOUS SYSTEM 
GLASGOW COMA SCORE 
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APACHE - II 
NEED VENTILATOR:  
DURATION OF MECHANICAL VEALNTILATION: 
LENGTH OF STAY IN IMCU/HOSPITAL 
MORTALITY 
 
INVESTIGATIONS:  
COMPLETE HAEMOGRAM 
RENAL FUNCTION TEST 
SERUM ELECTROLYTES-MAGNESIUM, CALCIUM,POTASSIUM,SODIUM 
FBS, PPBS 
LIVER FUNCTION TEST 
URINE ROUTINE 
ECG 
CHEST X-RAY 
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BLOOD CULTURE, URINE CULTURE, CT BRAIN WHEN INDICATED 
2D ECHOCARDIOGRAPHY:    
ABG ANALYSIS 
 
 
 
SIGNATURE OF INVESTIGATOR                          SIGNATURE OF GUIDE 
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LIST OF ABBREVIATIONS 
Mg  Magnesium 
APACHE Acute Physiology and Chronic Health Evaluation 
TPN Total Parental Nutrition 
TRPM Transient Receptor Potential channel Melastatin member 
CaSR Calcium Sensing Receptor 
ATP Adenosine Triphosphate 
PT Proximal Tubule  
TAL Thick Ascending Limb 
DCT Distal convoluted Tubule 
NKCC2 Na+K+2Cl-cotransporter 
ROMK Renal Outer Medullary K+ 
EGF Epidermal Growth Factor 
PTH Para Thyroid Hormone 
FEV 1 Forced Expiratory Volume – one second 
ISIS-4 Fourth International Study of Infarct Survival 
ACE Angiotensin Converting Enzyme 
H/o Alc history of alcohol intake  
N for V S need for ventilator support 
Dura. V S duration of ventilator support 
1
2
9
 
 
1
3
0
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